Results 21 to 30 of about 740,069 (270)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. [PDF]

Blood Adv, 2022
N ...
Fresa A, Autore F, Piciocchi A, Catania G, Visentin A, Tomasso A, Moretti M, Vitale C, Chiarenza A, Morelli F, Sportoletti P, Marasca R, Sapienza G, Cuccaro A, Murru R, Sanna A, Patti C, Angeletti I, Coscia M, Trentin L, Pietrasanta D, Innocenti I, Laurenti L.   +22 more
europepmc   +7 more sources

Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma. [PDF]

In Vivo
The impact of enfortumab vedotin (EV) dose reduction and/or interruption on its efficacy for advanced urothelial carcinoma (UC) is unclear.We retrospectively analyzed consecutive patients with advanced UC who received EV after the failure of platinum-based chemotherapy and immune checkpoint inhibitors from December 2021 to June 2024.
Furubayashi N, Negishi T, Mochida M, Kijima A, Katsuki H, Nakamura M.   +5 more
europepmc   +3 more sources

The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis

Current Oncology, 2021
There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were ...
Suganija Lakkunarajah, Daniel A. Breadner, Hanbo Zhang, Ellen Yamanaka, Andrew Warner, Stephen Welch   +5 more
doaj   +1 more source

Pegfilgrastim Maintains Relative Dose Intensity and Decreases Hospitalisations in Patients With Endometrial Cancer. [PDF]

In Vivo, 2020
Data are limited regarding the use of pegfilgrastim in gynaecologic oncology. We evaluated its efficacy for maintaining dose intensity during chemotherapy.We retrospectively examined the data of 65 women (26 pegfilgrastim users) who underwent primary surgical treatment for stages IB-IV endometrial cancer and had adjuvant chemotherapy containing ...
Chikazawa K, Imai K, Ito T, Kimura A, Hiroyoshi KO, Miho Y, Kuwata T, Konno R.   +7 more
europepmc   +4 more sources

Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma. [PDF]

Oncol Lett, 2022
The present retrospective study was undertaken to investigate the association of relative dose intensity (RDI) with the outcome of patients with advanced stage Hodgkin lymphoma (HL) receiving ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and escalated BEACOPP regimens (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine ...
Rožman S, Jezeršek Novaković B, Ružić Gorenjec N, Novaković S.   +3 more
europepmc   +4 more sources

The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis

BMC Cancer, 2022
Background Colorectal cancer remains the second leading cause of cancer death in North America. Fluorouracil and oxaliplatin based adjuvant chemotherapy for resected colon cancer (CC) reduces cancer recurrence, but also causes significant toxicity ...
Daniel Breadner, Jonathan M. Loree, Winson Y. Cheung, Meghan Gipson, Suganija Lakkunarajah, Karen E. Mulder, Jennifer L. Spartlin, Shiying Kong, Philip Q. Ding, Sharlene Gill, Stephen A. Welch   +10 more
doaj   +1 more source

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity. [PDF]

Medicine (Baltimore), 2016
Recently, it has been reported that the relative dose intensity (RDI) of adjuvant chemotherapy (AC) influences survival in various cancers, but there are very few reports about RDI in pancreatic ductal adenocarcinoma (PDAC). The optimal timing for initiation of AC for PDAC also remains unknown.
Yabusaki N, Fujii T, Yamada S, Murotani K, Sugimoto H, Kanda M, Nakayama G, Koike M, Fujiwara M, Kodera Y.   +9 more
europepmc   +3 more sources

Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study

BMC Cancer, 2022
Background S-1 adjuvant chemotherapy is the standard treatment in Asia for resectable pancreatic ductal adenocarcinoma. The relative dose intensity of adjuvant chemotherapy influences survival in pancreatic cancer but does not precisely reflect treatment
Kazuki Kobayashi, Takahiro Einama, Yasuhiro Takihata, Naoto Yonamine, Ibuki Fujinuma, Takazumi Tsunenari, Keita Kouzu, Akiko Nakazawa, Toshimitsu Iwasaki, Hideki Ueno, Yoji Kishi   +10 more
doaj   +1 more source

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy [PDF]

Annals of Hematology, 2008
R. Pettengell, M. Schwenkglenks, A. Bosly, MS Aapro, M Marangolo, R Pettengell, M Pfreundschuh, M Pfreundschuh   +7 more
core   +4 more sources

Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel [PDF]

Anticancer Research, 2019
Dose-dense doxorubicin and cyclophosphamide (ddAC) followed by dose-dense paclitaxel (ddP) (ddAC-P) has improved disease-free survival of patients with breast cancer. The aim of this study was to evaluate the safety and relative dose intensity (RDI) of ddAC-P administered together with pegfilgrastim.Between May 2015 and Aug 2017, 44 patients were ...
Meiko, Nishimura, Takuma, Onoe, Hideki, Sakai, Minori, Arase, Sayuri, Watanabe, Misao, Soyama, Kazuki, Hashimoto, Mayuko, Miki, Kaori, Tane, Koichi, Hirokaga, Shintaro, Takao, Koji, Matsumoto   +11 more
openaire   +2 more sources